CMOTEC B — Scandinavian ChemoTech AB Income Statement
0.000.00%
Last trade - 00:00- SEK102.32m
- SEK98.66m
- SEK12.29m
Annual income statement for Scandinavian ChemoTech AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | — | — | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.049 | 0.473 | 2.82 | 6.57 | 12.3 |
| Cost of Revenue | |||||
| Gross Profit | 2.86 | -0.055 | 1.66 | 4.78 | 10.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17.1 | 21.4 | 23.1 | 19.4 | 18.7 |
| Operating Profit | -17.1 | -20.9 | -20.2 | -12.8 | -6.46 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.7 | -22.7 | -21.1 | -13.7 | -8.06 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.7 | -22.7 | -21.1 | -13.7 | -8.06 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.7 | -22.7 | -21.1 | -13.7 | -8.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.7 | -22.7 | -21.1 | -13.7 | -8.06 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.77 | -2.27 | -1.5 | -0.588 | -0.335 |
| Dividends per Share |